Alluvi tirzepatide has been emerged as a promising therapeutic option for the management of metabolic disorders. This preclinical evaluation assessed the efficacy and safety of tirzepatide 40mg in in vivo models of type 2 diabetes. The research demonstrated that tirzepatide 40mg markedly enhanced glycemic management and reduced insulin resistance.